GeNeuro targets retrovirus protein in MS

Recent positive data from a Phase 2b trial of patients with multiple sclerosis illustrates the role of pathogenic HERV-W protein in the genesis of the disease. The protein was neutralised by an antibody therapy developed by GeNeuro SA, the first time this has been shown in a clinical trial.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Switzerland